AR023837A1 - 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen - Google Patents

1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen

Info

Publication number
AR023837A1
AR023837A1 ARP000102117A ARP000102117A AR023837A1 AR 023837 A1 AR023837 A1 AR 023837A1 AR P000102117 A ARP000102117 A AR P000102117A AR P000102117 A ARP000102117 A AR P000102117A AR 023837 A1 AR023837 A1 AR 023837A1
Authority
AR
Argentina
Prior art keywords
imidazoles
receptors
agonists
endothelial
tienilbencil
Prior art date
Application number
ARP000102117A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999120815 external-priority patent/DE19920815A1/de
Priority claimed from DE1999161686 external-priority patent/DE19961686A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR023837A1 publication Critical patent/AR023837A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a nuevos 1-(p-tienilbencil)-imidazoles de la Formula general (1) teniendo los radicales R1 a R6, X e Y tienen el significadoindicado en la descripcion, que son potentes agonistas de los receptores de la angiotensina-(1-7) y quemediante la produccion y liberacion vinculadas a laestimulacion de estos receptores en las células endoteliales, del monofosfato cíclico de 3,5-guanosina (cGMP) y del NO (monoxido de nitrogeno), que sonsustancias mensajeras vasorelajantes, antitromboticas y cardioprotectoras, representan valiosos medicamentos para el tratamiento y profilaxis de la elevadatension sanguínea, hipertrofía cardiaca, insuficiencia cardiaca, enfermedades coronarias cardiacas tales como la angina pectoral, infarto cardiaco, restenosisvascular después de una angioplastia, cardiomiopatías, una disfuncion endotelial o lesiones endoteliales, por ejemplo como consecuencia de procesosaterioscleroticos o en el caso de diabetes mellitus, como también de trombosis arterialy venosa.
ARP000102117A 1999-05-05 2000-05-03 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen AR023837A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999120815 DE19920815A1 (de) 1999-05-05 1999-05-05 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE1999161686 DE19961686A1 (de) 1999-12-21 1999-12-21 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-1(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
AR023837A1 true AR023837A1 (es) 2002-09-04

Family

ID=26053245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102117A AR023837A1 (es) 1999-05-05 2000-05-03 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen

Country Status (25)

Country Link
US (3) US6235766B1 (es)
EP (1) EP1185527B1 (es)
JP (1) JP2002544130A (es)
KR (1) KR20020012207A (es)
CN (1) CN1158279C (es)
AR (1) AR023837A1 (es)
AT (1) ATE300535T1 (es)
AU (1) AU775244B2 (es)
BR (1) BR0010248A (es)
CA (1) CA2373010A1 (es)
CZ (1) CZ20013907A3 (es)
DE (1) DE50010835D1 (es)
EE (1) EE200100572A (es)
HK (1) HK1045519B (es)
HR (1) HRP20010814A2 (es)
HU (1) HUP0201311A3 (es)
IL (1) IL146198A0 (es)
NO (1) NO20015309L (es)
NZ (1) NZ515242A (es)
PL (1) PL351609A1 (es)
RU (1) RU2247121C2 (es)
SK (1) SK15942001A3 (es)
TR (1) TR200103171T2 (es)
WO (1) WO2000068226A1 (es)
YU (1) YU78601A (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
DE10112041A1 (de) * 2001-03-14 2002-09-26 Aventis Pharma Gmbh p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU2002257970B2 (en) 2001-05-31 2007-08-02 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
JP4707321B2 (ja) * 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP1348440A1 (en) * 2002-03-28 2003-10-01 Citeq B.V. Use of angiotensin 1-7 for enhancing cardiac function
NL1021048C2 (nl) 2002-07-11 2004-01-13 Weir Netherlands B V Zuigermembraanpomp.
WO2004046137A1 (en) * 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2003302106A1 (en) * 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
WO2004085420A1 (en) * 2003-03-24 2004-10-07 Vicore Pharma Ab Bicyclic compounds useful as angiotensin ii agonists
US7176261B2 (en) 2004-10-21 2007-02-13 Medtronic, Inc. Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
ES2395194T3 (es) * 2005-04-12 2013-02-11 Vicore Pharma Ab Nuevos agonistas tricíclicos de la angiotensina II
BRPI0502497A (pt) * 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) * 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008052179A2 (en) * 2006-10-27 2008-05-02 Medtronic, Inc. Angiotensin (1-7) eluting stent
KR100885197B1 (ko) * 2008-09-25 2009-02-24 박창수 다면다각형상 구현이 용이한 엘이디조명 램프용 인쇄회로기판
EP2163259B1 (en) 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
WO2013090833A1 (en) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
AU2013216910A1 (en) * 2012-02-10 2014-08-28 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
US8557958B1 (en) * 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
MX2015014668A (es) * 2013-04-19 2016-06-30 Univ Iowa Res Found Angiotensinas en la distrofia muscular.
CN105451756A (zh) 2013-05-24 2016-03-30 塔瑞克斯制药有限公司 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
KR102697698B1 (ko) 2014-07-17 2024-08-21 유니버시티 오브 써던 캘리포니아 근골격 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
US10960045B2 (en) 2015-10-14 2021-03-30 Constant Therapeutics Llc Methods and compositions for the treatment of epidermolysis bullosa
KR102538999B1 (ko) 2016-06-29 2023-05-31 유니버시떼 드 몬트리얼 비아릴메틸 헤테로사이클
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
EP4117703A1 (en) 2020-03-13 2023-01-18 Constant Therapeutics LLC Methods and compositions for treatment of coronavirus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
WO1994027597A1 (en) * 1993-05-21 1994-12-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acid angiotensin ii receptor antagonists
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.

Also Published As

Publication number Publication date
HRP20010814A2 (en) 2003-02-28
HUP0201311A3 (en) 2003-03-28
WO2000068226A1 (de) 2000-11-16
EP1185527A1 (de) 2002-03-13
HK1045519A1 (en) 2002-11-29
KR20020012207A (ko) 2002-02-15
IL146198A0 (en) 2002-07-25
US20010018449A1 (en) 2001-08-30
ATE300535T1 (de) 2005-08-15
US6235766B1 (en) 2001-05-22
RU2247121C2 (ru) 2005-02-27
HK1045519B (zh) 2005-04-22
JP2002544130A (ja) 2002-12-24
TR200103171T2 (tr) 2002-06-21
US20020077344A1 (en) 2002-06-20
AU775244B2 (en) 2004-07-22
EE200100572A (et) 2003-02-17
NO20015309D0 (no) 2001-10-30
AU4753600A (en) 2000-11-21
DE50010835D1 (de) 2005-09-01
CN1349530A (zh) 2002-05-15
NZ515242A (en) 2003-11-28
US6429222B2 (en) 2002-08-06
BR0010248A (pt) 2002-02-13
HUP0201311A2 (en) 2002-10-28
YU78601A (sh) 2005-07-19
PL351609A1 (en) 2003-05-05
CN1158279C (zh) 2004-07-21
SK15942001A3 (sk) 2002-04-04
NO20015309L (no) 2001-12-28
CZ20013907A3 (cs) 2002-02-13
EP1185527B1 (de) 2005-07-27
CA2373010A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
AR023837A1 (es) 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
TR199801996A2 (xx) Pirazol t�revleri, �retimi ve ila� olarak kullan�m�
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
GT199900140A (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
ES2191944T3 (es) Forma cristalina de la sal de sodio de omeprazol.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
DE69627035D1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
UY27835A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
ECSP055912A (es) Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
PT2132221E (pt) Peptidomiméticos fixados num molde
DE59913103D1 (de) Substituierte 4-amino-2-aryl-cyclopenta ädüpyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
AU2003274686A8 (en) Inhibitors of the gpib -vwf interaction, their preparation and use
MY139310A (en) Pentafluorosulfanylbenzoylguanidines, process for their preparation, their use as. medicament or diagnostic aid, and medicament comprising them
DK1150963T3 (da) Substituerede 4-amino-2-aryltetrahydroquinazoliner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
PE20081261A1 (es) DERIVADOS DEL FLUORENO COMO INHIBIDORES DE LA PROTEINA CHAPERONA Hsp90 Y COMPOSICIONES QUE LOS CONTIENEN
ECSP066563A (es) Pentafluorosulfanil-benzoilguanidinas, método para su producción, su uso como medicamentos o agentes de diagnóstico, y medicamento que las contiene
ITMI931722A1 (it) Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
AR037943A1 (es) Derivados de pirimidinilsulfonamida, el uso de dichos compuestos solo o en combinacion para la produccion de medicamentos y un proceso para la manufactura de composiciones farmaceuticas
ES2156731B1 (es) Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
ES2146348T3 (es) Cromanilsulfonil(tio)ureas sustituidas, procedimiento para su preparacion y su utilizacion en preparados farmaceuticos, asi como preparados farmaceuticos que las contienen.
ES2138668T3 (es) Nuevos derivados de peptidos terapeuticamente activos en la cadena de coagulacion sanguinea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure